What compounds are known to provide coverage against anaerobes and Gram-positive bacteria?

What compounds are known to provide coverage against anaerobes and Gram-positive bacteria?

• A. Ampicillin-sulbactam
• B. Linezolid
• C. Cefepime
• D. Vancomycin

Answer: (A)

Ampicillin-sulbactam is a combination antibiotic that provides broad-spectrum coverage, particularly against anaerobic bacteria and Gram-positive organisms. The ampicillin component is a penicillin that is effective against a variety of Gram-positive bacteria, including Streptococcus and Enterococcus species. The addition of sulbactam, a beta-lactamase inhibitor, extends the spectrum of activity by protecting ampicillin from degradation by certain beta-lactamase producing bacteria. This combination is particularly useful in treating infections where both anaerobes and Gram-positive bacteria are suspected, such as intra-abdominal infections, diabetic foot infections, and certain respiratory tract infections. In contrast, while linezolid provides excellent coverage against Gram-positive bacteria, including resistant strains like MRSA, it does not have significant activity against anaerobic bacteria. Cefepime, a fourth-generation cephalosporin, has good activity against Gram-negative bacteria but is less effective against anaerobes and does not target many Gram-positive bacteria as effectively as ampicillin does. Vancomycin is primarily used for serious Gram-positive infections, particularly MRSA, but it also lacks coverage for anaerobic microorganisms. Thus, ampicillin-sulbactam is uniquely positioned to address

Ampicillin-sulbactam is a combination antibiotic that provides broad-spectrum coverage, particularly against anaerobic bacteria and Gram-positive organisms. The ampicillin component is a penicillin that is effective against a variety of Gram-positive bacteria, including Streptococcus and Enterococcus species. The addition of sulbactam, a beta-lactamase inhibitor, extends the spectrum of activity by protecting ampicillin from degradation by certain beta-lactamase producing bacteria. This combination is particularly useful in treating infections where both anaerobes and Gram-positive bacteria are suspected, such as intra-abdominal infections, diabetic foot infections, and certain respiratory tract infections.

In contrast, while linezolid provides excellent coverage against Gram-positive bacteria, including resistant strains like MRSA, it does not have significant activity against anaerobic bacteria. Cefepime, a fourth-generation cephalosporin, has good activity against Gram-negative bacteria but is less effective against anaerobes and does not target many Gram-positive bacteria as effectively as ampicillin does. Vancomycin is primarily used for serious Gram-positive infections, particularly MRSA, but it also lacks coverage for anaerobic microorganisms. Thus, ampicillin-sulbactam is uniquely positioned to address